Intrasense: Revenue Down 59.3% and Shift Towards AI in Oncology
Intrasense published its first-half 2026 accounts on September 28, marked by revenue down 59.3% and increased losses.
Beyond the figures, the Company marks a strategic shift: following the abandonment of the divestment project for its flagship Myrian activity, it is now concentrating its resources on two artificial intelligence solutions in oncology, DUOnco Pancreas and DUOnco Unity.
Revenue of €646K and Deepening Losses
First-half 2026 revenue stands at €646K, compared to €1,585K a year earlier, representing a decline of 59.3%. All of these revenues were generated by the Myrian activity.
According to the Company, this decline is mainly due to the loss of a major maintenance contract in France, the postponement of several license upgrade projects, and calendar effects internationally. The ongoing reorganization and the Myrian divestment project mobilized teams and contributed to the delay of several commercial opportunities.
EBITDA came in at -€4,474K, compared to -€2,355K in the first half of 2025. Operating income stood at -€6,347K (compared to -€2,717K) and net income at -€6,365K (compared to -€2,596K). Shareholders' equity stood at -€12,822K, compared to -€6,457K.
Cost Reduction and Cash Position Supported by Guerbet
Intrasense continued implementing the restructuring plan initiated in late 2025, following the approval of the employment safeguarding plan in March 2026. Excluding exceptional restructuring charges, personnel costs and external charges declined 17% compared to the first half of 2025.
Consumed purchases amount to €182K, compared to €287K a year earlier. Other operating income and expenses came in at -€421K, compared to +€1,206K in the first half of 2025, due to the combined effect of lower capitalized production and cleanup of aged invoices subject to provision reversal.
As of June 30, 2026, gross cash stands at €1,012K, compared to €797K on December 31, 2025, supported by current account advances provided by Guerbet, of which the Company has been a subsidiary since 2023. Intrasense has also completed repayment of its state-guaranteed loans, with the final installment paid in June 2026. Resilience PGEs remain in repayment, according to a schedule running through December 2028.
Refocus on DUOnco Pancreas and DUOnco Unity
Following the abandonment, announced on August 3, 2026, of the Myrian divestment project to EDL, Intrasense conducted a review of its product portfolio. The Company decided to refocus its strategy and resources on DUOnco Pancreas and DUOnco Unity, and to initiate the progressive discontinuation (End of Life) of Myrian, Liflow, DUOnco Liver, and DUOnco Bone.
Two regulatory advances accompany this refocus: DUOnco Pancreas, developed with Guerbet, obtained its regulatory authorization in Japan in June 2026, complementing the European CE marking; DUOnco Unity, a multi-organ solution for oncological monitoring on thoraco-abdominal-pelvic scans, obtained its MDR CE marking on August 21, 2026.
The Company announced in September 2026 the launch of a new workforce adjustment project, with deployment planned by the end of 2026. Intrasense indicates that 2026 constitutes a transition year: second-half activity will still include Myrian, while the contribution of DUOnco solutions is expected to be reflected primarily through the signing of framework agreements, order placement, and installation of pilot sites.
